Part II. What Do We Get for All That Money? A preventable epidemic of injury and death from prescription drugs; FDA’s contribution to the epidemic; Big Pharma’s business model: manufactured myths, propaganda and a hidden agenda;
Since 1995 FDA scientists have been at odds against FDA managers who routinely override sientists’ safety concerns to approve dubious prescription drugs.
Since 1995 FDA scientists have been at odds against FDA managers who routinely override sientists’ safety concerns to approve dubious prescription drugs. Continue reading →
Autism: Vaccine Injury Compensation Program (VICP) data. Continue reading →
The latest area of controversy focuses on the proposed revision of the definition "behavioral addiction disorder" extending the addiction diagnosis to include drug, alcohol and gambling. It is estimated that the change would expand the number of people labeled as "addicts" by 20 to 30 million who would be entitled to treatment and disability payments costing taxpayers many hundreds of millions of dollars. Continue reading →
Three new studies–one,, a pharmaco-genetic study, is groundbreaking–confirm that widely prescribed psychotropic drugs that pose serious risks of harm, offer no therapeutic benefit.
Project on Government Oversight (POGO) asked NIH Director to take a firm stance against ghostwriting by academics who receive taxpayer funded grants.
A meta- analysis of 61 studies in PLoS ONE found an increased risk of breast cancer for women taking an antidepressant. Continue reading →
"Prescription Drugs Associated with Reports of Violence Towards Others, " identifies 31 drugs linked to 1,527 acts of violence… Continue reading →
“To ghostwrite an entire textbook is a new level of chutzpah,” said Dr. David A. Kessler, former commissioner of the Food and Drug Administration, after reviewing the documents. “I’ve never heard of that before. It takes your breath away.” Continue reading →
Despite the fact that children may be at highest risk of antidepressant-induced suicide, GlaxoSmithKline is testing Paxil on 7 to 18 year old Japanese children. Continue reading →
The comments below expand upon an Infomail about the recently published JAMA meta-analysis.
